Bulbar and spinal muscular atrophy (Kennedy's disease): A review

European Journal of Neurology

Volumn 16, Issue 5, 2009, Pages 556-561

  Finsterer, J ^a,b  

^a Krankenanstalt Rudolfstiftung ^*  (Austria)

^b KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

Anterior horn cell disease; Motor neuron disease; Poly Q disease; Trinucleotide repeat disorder

Indexed keywords

ALPHA TOCOPHEROL; ANDROGEN RECEPTOR; BUTYRIC ACID; LEUPRORELIN; PROGESTERONE; TESTOSTERONE; VITAMIN B GROUP;

CHROMOSOME XQ; CLINICAL FEATURE; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; ENDOCRINE DISEASE; GENE MUTATION; GENETIC ANALYSIS; GYNECOMASTIA; HUMAN; INFERTILITY; KENNEDY DISEASE; LIFE EXPECTANCY; MOTOR NEURON DISEASE; MUSCLE ATROPHY; MUSCLE CRAMP; MUSCLE WEAKNESS; MYOPATHY; NEUROPATHY; NONHUMAN; ONSET AGE; PATHOPHYSIOLOGY; PHYSIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; SENSORY DYSFUNCTION; TANDEM REPEAT; X CHROMOSOME RECESSIVE DISORDER;

ANIMALS; BULBO-SPINAL ATROPHY, X-LINKED; HUMANS; RECEPTORS, ANDROGEN;

EID: 64149099061     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2009.02591.x     Document Type: Review

References (54)

1. Sinclair R, Greenland KJ, Egmond S, Hoedemaker C, Chapman A, Zajac JD. Men with Kennedy disease have a reduced risk of androgenetic alopecia. Br J Dermatol 2007 157 : 290 294.
2. Palazzolo I, Gliozzi A, Rusmini P, et al. The role of the polyglutamine tract in androgen receptor. J Steroid Biochem Mol Biol 2008 108 : 245 253.
3. Adachi H, Waza M, Tokui K, et al. CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model. J Neurosci 2007 27 : 5115 5126.
4. LaFevre-Bernt MA, Ellerby LM. Kennedy's disease. Phosphorylation of the polyglutamine-expanded form of androgen receptor regulates its cleavage by caspase-3 and enhances cell death. J Biol Chem 2003 278 : 34918 34924.
5. Jordan CL, Lieberman AP. Spinal and bulbar muscular atrophy: a motoneuron or muscle disease? Curr Opin Pharmacol 2008 8 : 752 758.
6. Li XH, Zhuang JJ, Xie QY, et al. Clinical manifestations and molecular genetics of spinal bulbar muscular atrophy: report of 5 cases. Zhonghua Yi Xue Za Zhi 2007 87 : 1611 1615.
7. Thomas PS Jr., Fraley GS, Damian V, et al. Loss of endogenous androgen receptor protein accelerates motor neuron degeneration and accentuates androgen insensitivity in a mouse model of X-linked spinal and bulbar muscular atrophy. Hum Mol Genet 2006 15 : 2225 2238.
8. Guidetti D, Sabadini R, Ferlini A, Torrente I. Epidemiological survey of X-linked bulbar and spinal muscular atrophy, or Kennedy disease, in the province of Reggio Emilia, Italy. Eur J Epidemiol 2001 17 : 587 591.
9. Udd B, Juvonen V, Hakamies L, et al. High prevalence of Kennedy's disease in Western Finland - is the syndrome underdiagnosed? Acta Neurol Scand 1998 98 : 128 133.
10. Kennedy WR, Alter M, Sung JH. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 1968 18 : 671 680.
11. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991 352 : 77 79.
12. Igarashi S, Tanno Y, Onodera O, et al. Strong correlation between the number of CAG repeats in androgen receptor genes and the clinical onset of features of spinal and bulbar muscular atrophy. Neurology 1992 42 : 2300 2302.
13. Bingham PM, Scott MO, Wang S, et al. Stability of an expanded trinucleotide repeat in the androgen receptor gene in transgenic mice. Nat Genet 1995 9 : 191 196.
14. Walcott JL, Merry DE. Trinucleotide repeat disease. The androgen receptor in spinal and bulbar muscular atrophy. Vitam Horm 2002 65 : 127 147.
15. Puls I, Oh SJ, Sumner CJ, et al. Distal spinal and bulbar muscular atrophy caused by dynactin mutation. Ann Neurol 2005 57 : 687 694.
16. Katsuno M, Banno H, Suzuki K, et al. Molecular genetics and biomarkers of polyglutamine diseases. Curr Mol Med 2008 8 : 221 234.
17. Suzuki K, Katsuno M, Banno H, et al. CAG repeat size correlates to electrophysiological motor and sensory phenotypes in SBMA. Brain 2008 131 : 229 239.
18. Manning JT. The androgen receptor gene: a major modifier of speed of neuronal transmission and intelligence? Med Hypotheses 2007 68 : 802 804.
19. Davies P, Watt K, Kelly SM, Clark C, Price NC, McEwan IJ. Consequences of poly-glutamine repeat length for the conformation and folding of the androgen receptor amino-terminal domain. J Mol Endocrinol 2008 41 : 301 314.
20. Adachi H, Katsuno M, Minamiyama M, et al. Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain 2005 128 : 659 670.
21. Yamada M, Sato T, Tsuji S, Takahashi H. CAG repeat disorder models and human neuropathology: similarities and differences. Acta Neuropathol 2008 115 : 71 86.
22. Panet-Raymond V, Gottlieb B, Beitel LK, et al. Characterization of intracellular aggregates using fluorescently-tagged polyglutamine-expanded androgen receptor. Neurotox Res 2001 3 : 259 275.
23. Zhou YF, Jiang H, Tang JG, Tang BS. The advances in research on phosphorylation of polyglutamine disease. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2008 25 : 414 417.
24. Palazzolo I, Burnett BG, Young JE, et al. Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity. Hum Mol Genet 2007 16 : 1593 1603.
25. Katsuno M, Adachi H, Minamiyama M, et al. Reversible disruption of dynactin 1-mediated retrograde axonal transport in polyglutamine-induced motor neuron degeneration. J Neurosci 2006 26 : 12106 12117.
26. Ranganathan S, Harmison GG, Meyertholen K, Pennuto M, Burnett BG, Fischbeck KH. Mitochondrial abnormalities in spinal and bulbar muscular atrophy. Hum Mol Genet 2009 18 : 27 42.
27. Liu CS, Cheng WL, Kuo SJ, Li JY, Soong BW, Wei YH. Depletion of mitochondrial DNA in leukocytes of patients with poly-Q diseases. J Neurol Sci 2008 264 : 18 21.
28. Badalian LO, Temin PA, Arkhipov BA, Zavadenko NN, Bulaeva NV, Lysov VL. Familial case of late recessive X-linked Kennedy's spinal and bulbar amyotrophy. Zh Nevropatol Psikhiatr Im S S Korsakova 1989 89 : 39 44.
29. Larsen K, Smith TA. "Jaw drop" as an atypical manifestation of Kennedy's disease. Ugeskr Laeger 2005 167 : 3310 3311.
30. Lee JH, Shin JH, Park KP, et al. Phenotypic variability in Kennedy's disease: implication of the early diagnostic features. Acta Neurol Scand 2005 112 : 57 63.
31. Tomik B, Partyka D, Sułek A, et al. A phenotypic-genetic study of a group of Polish patients with spinal and bulbar muscular atrophy. Amyotroph Lateral Scler 2006 7 : 72 79.
32. Atsuta N, Watanabe H, Ito M, et al. Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain 2006 129 : 1446 1455.
33. Echaniz-Laguna A, Bousiges O, Loeffler JP, Boutillier AL. Histone deacetylase inhibitors: therapeutic agents and research tools for deciphering motor neuron diseases. Curr Med Chem 2008 15 : 1263 1273.
34. Karaer H, Kaplan Y, Kurt S, Gundogdu A, Erdòan B, Basak NA. Phenotypic differences in a large family with Kennedy's disease from the Middle Black Sea region of Turkey. Amyotroph Lateral Scler 2008 26 : 1 6.
35. Paradas C, Solano F, Carrillo F, et al. Highly skewed inactivation of the wild-type X-chromosome in asymptomatic female carriers of spinal and bulbar muscular atrophy (Kennedy's disease). J Neurol 2008 255 : 853 857.
36. Sorarù G, D'Ascenzo C, Polo A, et al. Spinal and bulbar muscular atrophy: skeletal muscle pathology in male patients and heterozygous females. J Neurol Sci 2008 264 : 100 105.
37. Sorenson EJ, Klein CJ. Elevated creatine kinase and transaminases in asymptomatic SBMA. Amyotroph Lateral Scler 2007 8 : 62 64.
38. Lai TH, Soong BW, Chen JT, et al. Multimodal evoked potentials of Kennedy's disease. Can J Neurol Sci 2007 34 : 328 332.
39. Hamano T, Mutoh T, Hirayama M, et al. Muscle MRI findings of X-linked spinal and bulbar muscular atrophy. J Neurol Sci 2004 222 : 93 97.
40. Banno H, Adachi H, Katsuno M, et al. Mutant androgen receptor accumulation in spinal and bulbar muscular atrophy scrotal skin: a pathogenic marker. Ann Neurol 2006 59 : 520 526.
41. Katsuno M, Adachi H, Tanaka F, Sobue G. Spinal and bulbar muscular atrophy: ligand-dependent pathogenesis and therapeutic perspectives. J Mol Med 2004 82 : 298 307.
42. Katsuno M, Adachi H, Doyu M, et al. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 2003 9 : 768 773.
43. Shimohata T, Kimura T, Nishizawa M, Onodera O, Tsuji S. Five year follow up of a patient with spinal and bulbar muscular atrophy treated with leuprorelin. J Neurol Neurosurg Psychiatry 2004 75 : 1206 1207.
44. Minamiyama M, Katsuno M, Adachi H, et al. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 2004 13 : 1183 1192.
45. Howarth JL, Kelly S, Keasey MP, et al. Hsp40 molecules that target to the ubiquitin-proteasome system decrease inclusion formation in models of polyglutamine disease. Mol Ther 2007 15 : 1100 1105.
46. Adachi H, Katsuno M, Minamiyama M, et al. Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein. J Neurosci 2003 23 : 2203 2211.
47. Katsuno M, Sang C, Adachi H, et al. Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proceedings of the National Academy of Sciences of the United States of America 2005 102 : 16801 16806.
48. Waza M, Adachi H, Katsuno M, et al. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med 2005 11 : 1088 1095.
49. Yang Z, Chang YJ, Yu IC, et al. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med 2007 13 : 348 353.
50. Rusmini P, Sau D, Crippa V, et al. Aggregation and proteasome: the case of elongated polyglutamine aggregation in spinal and bulbar muscular atrophy. Neurobiol Aging 2007 28 : 1099 1111.
51. Kinirons P, Rouleau GA. Administration of testosterone results in reversible deterioration in Kennedy's disease. J Neurol Neurosurg Psychiatry 2008 79 : 106 107.
52. Chahin N, Klein C, Mandrekar J, Sorenson E. Natural history of spinal-bulbar muscular atrophy. Neurology 2008 70 : 1967 1971.
53. Takeuchi Y, Katsuno M, Banno H, et al. Walking capacity evaluated by the 6-minute walk test in spinal and bulbar muscular atrophy. Muscle Nerve 2008 38 : 964 971.
54. Monks DA, Rao P, Mo K, Johansen JA, Lewis G, Kemp MQ. Androgen receptor and Kennedy disease/spinal bulbar muscular atrophy. Horm Behav 2008 53 : 729 740.